Hibiki Authorization Partners
Hibiki Path Advisors
Hibiki Path Advisors is an engagement investor focused on Japan's small and mid-cap segment. They integrate with 3D Investment Partners in January 2026.
Hibiki Path Advisors (HPA) has been an engagement investor in Japan's small and mid-cap segment for approximately 10 years, focusing on enhancing corporate value and improving the Japanese capital market. As of January 2026, HPA will integrate its business with 3D Investment Partners Pte. Ltd. (3DIP), a major independent asset manager with a similar investment philosophy. The core members of HPA, including Yuya Shimizu and Victor Foo, will continue their investment activities in the small and mid-cap segment as an independent investment decision-making unit within 3DIP. This strategy will be named the "3D Hibiki Path Aoba Strategy," with Yuya Shimizu serving as CIO. HPA has a history of engaging with investee companies and has published their engagement trends. They have also provided commentary on earnings results for companies like Star Mica Holdings and Tokyo Cosmos Electric, demonstrating their active role in the market. Their investment philosophy emphasizes long-term value creation and contributing to the improvement of the Japanese capital market.
About
**Who they are**
Hibiki Authorization Partners is an engagement investor focused on Japan's small and mid-cap segment. They integrate with 3D Investment Partners.
**Expertise & scope**
- Specializes in the Japanese market.
- Focuses on small and mid-cap companies.
**Reputation / proof points**
- Integration with 3D Investment Partners in January 2026.
Hibiki Authorization Partners is an engagement investor focused on Japan's small and mid-cap segment. They integrate with 3D Investment Partners.
**Expertise & scope**
- Specializes in the Japanese market.
- Focuses on small and mid-cap companies.
**Reputation / proof points**
- Integration with 3D Investment Partners in January 2026.
Additional information
Hibiki Authorization Partners operates within the Japanese market, focusing on engagement investment strategies for small and mid-cap companies. Their integration with 3D Investment Partners in early 2026 signifies a strategic expansion and enhanced capabilities within the investment landscape. Buyers engaging with Hibiki Authorization Partners can expect a specialized approach tailored to the nuances of the Japanese financial sector.
Key Highlights
-
Specializes in regulatory affairs for the Japanese market.
Source
“Hibiki Path Advisors is an engagement investor focused on Japan's small and mid-cap segment.”
-
Integrates with 3D Investment Partners.
Source
“They integrate with 3D Investment Partners in January 2026.”
-
Provides coverage for Japan (JP).
Source
“Coverage: JP”
-
Supports multiple languages including Japanese, English, and Chinese.
Source
“Languages: Japanese, English, Chinese”
Certifications & Trust Signals
-
Focus on Japan's small and mid-cap segment.
Source
“Hibiki Path Advisors is an engagement investor focused on Japan's small and mid-cap segment.”
Buyer Snapshot
Best for
- Companies seeking MAH/DMAH services in Japan
- Small and mid-cap companies targeting the Japanese market
How engagement typically works
- Regulatory strategy development
- Compliance support
Typical deliverables
- MAH/DMAH authorization support
- Regulatory documentation assistance
Good to know
- Best when focused on the Japanese regulatory environment
HQ:
Kyoto, JP
Languages:
Japanese, English, Chinese
Timezones:
Asia/Tokyo
Claim status:
Listed
Services & Capabilities
Find Japan MAH / DMAH Providers | Get Quotes
Jurisdictions:
JP
Countries:
JP
Industries:
Medical devices, IVD, Life sciences
Portfolio:
6-25
Onboarding time:
10–45 days
Pricing model:
Per project
Starting from:
USD 8,500
Included services:
MAH/DMAH appointment support, PMDA liaison and communications routing, Local license/establishment maintenance support, Translation enablement (scope-dependent), GMP/QMS coordination support (scope-dependent)
Offers MAH:
No
Offers DMAH:
No
PMDA Support:
No
Local License Capability:
No
Translation Support:
No
GMP Qmssupport:
No
Regulatory Liaison PMDA:
No
